tositumomab

Home
Ligands
tositumomab

GtoPdb Ligand ID: 6781

Synonyms: Bexxar® | V10XA53

tositumomab is an approved drug (FDA (2003))

Comment: Tositumomab was used as a radioimmunotherapy drug, targeting CD20 on B-lymphocytes prior to cessation of its manufacture.

References
1. Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast Jr R, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. (1985) Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res, 45 (2): 758-67. [PMID:3967246]
2. Kaminski MS, Butchko GM, Glenn SD, Wahl RL. (1998) Radioimmunotherapy of lymphoma using anti-CD20 antibodies. Patent number: US5843398. Assignee: Coulter Pharmaceutical, Inc., Regents Of The University Of Michigan. Priority date: 16/09/1993. Publication date: 01/12/1998.
3. Stashenko P, Nadler LM, Hardy R, Schlossman SF. (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol, 125 (4): 1678-85. [PMID:6157744]

References

1. Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast Jr R, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. (1985)
Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
Cancer Res, 45 (2): 758-67. [PMID:3967246]

2. Kaminski MS, Butchko GM, Glenn SD, Wahl RL. (1998)
Radioimmunotherapy of lymphoma using anti-CD20 antibodies.
Patent number: US5843398. Assignee: Coulter Pharmaceutical, Inc., Regents Of The University Of Michigan. Priority date: 16/09/1993. Publication date: 01/12/1998.

3. Stashenko P, Nadler LM, Hardy R, Schlossman SF. (1980)
Characterization of a human B lymphocyte-specific antigen.
J Immunol, 125 (4): 1678-85. [PMID:6157744]